JP2023510289A5 - - Google Patents

Info

Publication number
JP2023510289A5
JP2023510289A5 JP2022542050A JP2022542050A JP2023510289A5 JP 2023510289 A5 JP2023510289 A5 JP 2023510289A5 JP 2022542050 A JP2022542050 A JP 2022542050A JP 2022542050 A JP2022542050 A JP 2022542050A JP 2023510289 A5 JP2023510289 A5 JP 2023510289A5
Authority
JP
Japan
Prior art keywords
immunogenic agent
agent according
immunogenic
hydrophobic
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/050012 external-priority patent/WO2021138721A1/en
Publication of JP2023510289A publication Critical patent/JP2023510289A/ja
Publication of JP2023510289A5 publication Critical patent/JP2023510289A5/ja
Pending legal-status Critical Current

Links

JP2022542050A 2020-01-09 2021-01-08 ワクチン送達のための自己組織化自己アジュバント系 Pending JP2023510289A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900058 2020-01-09
AU2020900058A AU2020900058A0 (en) 2020-01-09 Self-assembling, self-adjuvanting system for delivery of vaccines
PCT/AU2021/050012 WO2021138721A1 (en) 2020-01-09 2021-01-08 Self-assembling, self-adjuvanting system for delivery of vaccines

Publications (2)

Publication Number Publication Date
JP2023510289A JP2023510289A (ja) 2023-03-13
JP2023510289A5 true JP2023510289A5 (enExample) 2024-01-09

Family

ID=76787402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542050A Pending JP2023510289A (ja) 2020-01-09 2021-01-08 ワクチン送達のための自己組織化自己アジュバント系

Country Status (6)

Country Link
US (1) US20230090311A1 (enExample)
EP (1) EP4087606A1 (enExample)
JP (1) JP2023510289A (enExample)
AU (1) AU2021205866A1 (enExample)
CA (1) CA3163999A1 (enExample)
WO (1) WO2021138721A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021050442A1 (en) * 2021-08-13 2023-06-05 Univ Of The Philippines Through The Univ Of The Philippines Manila ANTIPEPTIDE IMMUNOGLOBULINS TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE GLYCOPROTEIN (S PROTEIN) EPITOPES AND COGNATE IMMUNOGENS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND ANTIGEN DETECTION SYSTEMS RELATING THERETO
US20240139312A1 (en) * 2022-05-27 2024-05-02 Design-Zyme LLC Universal adjuvant for nasal, oral, and intramuscular delivery of vaccines
US20240156958A1 (en) * 2022-11-02 2024-05-16 Design-Zyme LLC Self-adjuvanting multi-protein complexes for modular vaccine production

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106668A (zh) * 2014-12-10 2017-08-29 华西亚生医有限公司 用于免疫中的有效抗体生产的新颖蛋白质结构
WO2018187515A1 (en) * 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
JP7194442B2 (ja) * 2017-08-07 2022-12-22 国立大学法人東京農工大学 抗原組成物
CN112566672A (zh) * 2018-05-22 2021-03-26 阿维迪科技公司 制造基于肽的疫苗的改进方法
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测
KR20250107297A (ko) * 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편

Similar Documents

Publication Publication Date Title
JP2023510289A5 (enExample)
JP5276598B2 (ja) コイルドコイル構造を有するリポペプチドビルディングブロック、リポペプチドヘリックスバンドル、合成ウイルス様粒子、および医薬製剤
KR101617790B1 (ko) 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
Spicer et al. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
WO2021115497A3 (zh) 蛋白-药物偶联物和定点偶联方法
CN107708671B (zh) 包含钴卟啉-磷脂缀合物和聚组氨酸标签的纳米结构
JP5751741B2 (ja) 免疫原性組成物および使用法
WO1999007728A2 (fr) Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
JP2010254700A (ja) 膜転位剤および製薬学的有効成分の複合物
JP2009521908A5 (enExample)
JP2002514892A (ja) 遺伝子治療における合成ウイルス様粒子の使用
WO2013065009A1 (en) A sortase-click reaction suite for synthesis of multivalent dendrimeric protein assembly
EP1286700A2 (en) Tumor activated prodrug compounds
JPH06220070A (ja) リン脂質誘導体及びそれを含有するリポソーム
RU2005130173A (ru) Использование лектинов для активации олигомеризации гликопротеидов и антигенных молекул
JP2003517300A5 (enExample)
JP2023532290A5 (enExample)
CA2654073A1 (en) Liposome-mediated native chemical ligation
JP2006515744A5 (enExample)
Salmaso et al. Nanotechnologies in protein delivery
EP0306912A2 (en) Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
JP2022514348A5 (enExample)
EP1704167B1 (en) A method to make a peptide-carrier conjugate with a high immunogenicity
CN100387616C (zh) 获得可增强特异交叉反应性的抗原结构的方法
RU2007106900A (ru) Иммуногенные комплексы, способ их приготовления и их применение в фармацевтических композициях